SEEL vs. ANNX, CTXR, EVLO, BIVI, THRX, OPT, GNTA, ALT, RLMD, and APLT
Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Annexon (ANNX), Citius Pharmaceuticals (CTXR), Evelo Biosciences (EVLO), BioVie (BIVI), Theseus Pharmaceuticals (THRX), Opthea (OPT), Genenta Science (GNTA), Altimmune (ALT), Relmada Therapeutics (RLMD), and Applied Therapeutics (APLT). These companies are all part of the "medical" sector.
Seelos Therapeutics vs.
Seelos Therapeutics (NASDAQ:SEEL) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
In the previous week, Seelos Therapeutics had 9 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Seelos Therapeutics and 3 mentions for Annexon. Annexon's average media sentiment score of 0.66 beat Seelos Therapeutics' score of -0.73 indicating that Annexon is being referred to more favorably in the news media.
18.0% of Seelos Therapeutics shares are owned by institutional investors. 6.4% of Seelos Therapeutics shares are owned by insiders. Comparatively, 19.1% of Annexon shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Seelos Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Annexon has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Seelos Therapeutics presently has a consensus price target of $2.33, indicating a potential upside of 1,128.07%. Annexon has a consensus price target of $14.33, indicating a potential upside of 497.22%. Given Seelos Therapeutics' higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than Annexon.
Seelos Therapeutics received 45 more outperform votes than Annexon when rated by MarketBeat users. Likewise, 66.36% of users gave Seelos Therapeutics an outperform vote while only 61.90% of users gave Annexon an outperform vote.
Annexon's return on equity of -64.31% beat Seelos Therapeutics' return on equity.
Summary
Seelos Therapeutics beats Annexon on 7 of the 13 factors compared between the two stocks.
Get Seelos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SEEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Seelos Therapeutics Competitors List
Related Companies and Tools